No­vo Nordisk notch­es big GLP-1 sales amid re­bound­ing sup­plies, but cau­tions on fu­ture 'pe­ri­od­ic con­straints'

With No­vo Nordisk’s obe­si­ty treat­ment We­govy ful­ly back in stock in De­cem­ber, sales are be­gin­ning to soar, the Dan­ish phar­ma re­port­ed dur­ing its an­nu­al earn­ings …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER